



US005919787A

United States Patent [19][11] **Patent Number:** **5,919,787****Hallinan et al.**[45] **Date of Patent:** **Jul. 6, 1999**[54] **AMINOTETRAZOLE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS**95/00505 1/1995 WIPO .
95/11014 4/1995 WIPO .
96/06076 2/1996 WIPO .[75] Inventors: **E. Ann Hallinan**, Evanston; **Donald W. Hansen, Jr.**, Skokie; **Sofya Tsymbalov**, Des Plaines, all of Ill.

OTHER PUBLICATIONS

[73] Assignee: **G. D. Searle & Co.**, Chicago, Ill.Gould et al., "Nucleoside Intermediates in Blastocidin S Biosynthesis Identified by the In Vivo Use of Enzyme Inhibitors", *Can. J. Chem.*, vol. 72, pp. 6-11, 1994.[21] Appl. No.: **09/166,036**Tsunematsu et al., "β-Naphthylamides of Guanidinophenyl Amino Acids as Substrates of Aminopeptidases", *Chem. Pharm. Bull.*, vol. 36, No. 3, pp. 1205-1209, 1988.[22] Filed: **Oct. 5, 1998**Funabashi et al., "A New Anti-MRSA Dipeptide, TAN-1057 A", *Tetrahedron*, vol. 49, No. 1, pp. 13-28, 1993.**Related U.S. Application Data**

[63] Continuation of application No. 08/817,971, Apr. 30, 1997, Pat. No. 5,854,251, which is a continuation of application No. PCT/US95/14001, Nov. 8, 1995, which is a continuation-in-part of application No. 08/336,596, Nov. 9, 1994, Pat. No. 5,684,008.

Prabhakaran et al., "Studies on Nitrogen Metabolism Using ¹³C NMR Spectroscopy. 1. Metabolism of L-α-Arginine in the Biosynthesis of Blastocidin S", *Tetrahedron*, vol. 27, No. 33, pp. 3815-3818, 1986.[51] **Int. Cl.**⁶ **A61K 31/41**; A61K 31/415; C07D 257/06; C07D 231/40Palacios, et al., "Nitric Oxide from L-Arginine Stimulates the Soluble Guanylate Cyclase in Adrenal Glands", *Biochemical and Biophysical Research Communications*, vol. 165, No. 2, pp. 802-809, 1989.[52] **U.S. Cl.** **514/256**; 514/371; 514/381; 514/383; 514/398; 514/407; 544/322; 548/262.8; 548/195; 548/332.5; 548/371.7Knowles et al., "Kinetic Characteristics of Nitric Oxide Synthase from Rat Brain", *Biochem. J.*, vol. 269, pp. 207-210, 1990.[58] **Field of Search** 514/256, 371, 514/381, 383, 398, 407; 544/322; 548/262.8, 195, 332.5, 371.7

Chemical Abstracts, 107:40336y, 1987.

Chemical Abstracts, 63:5641d, 1965.

Chemical Abstracts, 97:38442m, 1982.

Chemical Abstracts, 76:43768t, 1972.

Chemical Abstracts, 118:72838g, 1993.

Chemical Abstracts, 64:17593h, 1966.

Chemical Abstracts, 115:29868t, 1991.

Chemical Abstracts, 104:202858, 1986.

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,713,369 12/1987 Stüber 514/18
5,059,712 10/1991 Griffith 562/560
5,081,148 1/1992 Braquet et al. 514/162
5,132,453 7/1992 Griffith 562/560
5,196,450 3/1993 Sjoerdsma et al. 514/565
5,273,875 12/1993 Griffith 435/1
5,281,627 1/1994 Griffith 514/565
5,362,744 11/1994 Purchase, Jr. et al. 514/381
5,364,881 11/1994 Griffith et al. 514/508
5,464,858 11/1995 Griffith et al. 514/399

Stuehr et al., "Mammalian Nitric Oxide Synthases" 287-347.

Plapp et al., *Analytical Biochem* 62:291-294 (1974).Proudfoot et al., *J. Biol Chem* 264 No. 15:8764-8770 (1989).D.D. Rees, *Br. J. Pharmacol.* 101 No. 3:746-752 (1990).Plapp et al., *Anal. Biochem* 62 No. 1:291-294 (1974).

FOREIGN PATENT DOCUMENTS

0370320 5/1990 European Pat. Off. .
0446699 9/1991 European Pat. Off. .
2240041 7/1991 United Kingdom .
91/04023 4/1991 WIPO .
91/04024 4/1991 WIPO .
93/13055 7/1993 WIPO .
93/16721 9/1993 WIPO .
93/24126 12/1993 WIPO .
94/14780 7/1994 WIPO .*Primary Examiner*—Fiona T. Powers*Attorney, Agent, or Firm*—Alan L. Scrivner; Dennis A. Bennett[57] **ABSTRACT**

The current invention discloses aminotetrazole derivatives useful as nitric oxide synthase inhibitors.

10 Claims, No Drawings